Navigation Links


axon at Biology News

Telling axons where to go - and grow

In a recent study, Dr. Ingolf Bach and colleagues from the University of Massachusetts Medical School, Worcester and the University of Hamburg (Germany) describe a novel role for the ubiquitin/proteosome protein degradation pathway in the regulation of local actin dynamics in neurons. The authors are able to show that the ubiquitin ligase Rnf6 polyubiquitinates the kinase LIMK1, targeting...

Newly identified protein complex sheds light on axon growth mechanism

New research sheds light on the molecular mechanisms underlying axon growth and synapse formation in the nematode worm C.elegans. In a study published today in the open access journal Journal of Biology, researchers have characterised a new protein, UNC-69, required for proper locomotion . They show that UNC-69 interacts with UNC-76 in a protein complex likely to be involved in the trafficking of...
axon at Biology Products
axon at Biology Technology
axon at Biology Definition

Taxonomy

= law) may refer to either a hierarchical classification of things, or the principles underlying the classification. Almost anything, animate objects, inanimate objects, place...

Axon

or soma. Axons are in effect the primary transmission lines of the <a href="/ ?q=/ ...
axon at Biology Dictionary

Taxonomy

<A href="http:/ / www.webref.org/ biology/ t/ taxonomy.htm" ta...

Taxon

, 11th Edition. St. Louis, MO. C. V. Mosby ...<br...

Axon

Biology...
axon at Medicine News
axon at Medicine Products
axon at Medicine Technology

Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis

KANSAS CITY, Mo.--(BUSINESS WIRE)--May 4, 2007 - New data from arandomized, double-blind study showed that a combination ofCOPAXONE(R) (glatiramer acetate injection) along with the oralantibiotic minocycline reduced T1 Gadolinium (Gd)-enhancing lesionsof the brain by 63 percent (p=0.08) in patients with activerelapsing-remitting multiple sclerosis (RRMS), as measured bymagnetic resonance im...

Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis

Treatment with Copaxone Plus Minocycline Showed SubstantialReduction of Disease Activity in Patients with ActiveRelapsing-Remitting Multiple Sclerosis Combination Treatment With Antibiotic Further Reduced BrainLesions and Was Well Tolerated KANSAS CITY, Mo, May 4, 2007 - New data from a randomized,double-blind study showed that a combination of Copaxone(glatiramer acetate in...

Copaxone Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients

KANSAS CITY, Mo.--(BUSINESS WIRE)--May 4, 2007 - New data havedemonstrated that relapsing-remitting multiple sclerosis (RRMS)patients treated with COPAXONE(R) (glatiramer acetate injection)following brief immunosuppression with mitoxantrone experienced a90 percent reduction in magnetic resonance imaging (MRI)-monitoreddisease activity compared to their baseline. These benefits wereachieved...

Data on Higher Dose of Copaxone and Data Showing Copaxone is Most Cost Effective

Data Published in Neurology Showed That Higher Dose of CopaxoneIncreased Efficacy in Relapsing-remitting Multiple Sclerosis(RRMS) Doubled Dose of COPAXONE Maintained Proven Safety Profile andFurther Reduced Relapses and Lesions JERUSALEM, Israel, April 17, 2007 – A 9-month, randomized,double-blind, parallel-group Phase II study of 90 patientscomparing a...

Data Published in Neurology Showed That Higher Dose of Copaxone Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)

JERUSALEM--(BUSINESS WIRE)--Apr 17, 2007 - A 9-month, randomized,double-blind, parallel-group Phase II study of 90 patientscomparing a 40 mg dose of COPAXONE(R) given daily to the currentlyapproved COPAXONE(R) 20 mg dose showed a 38 percent greaterreduction in inflammatory disease activity as measured by magneticresonance images (MRI) of the brain. In addition, patients takingCOPAXONE(R) 40...

More>>

Other TagsSLASLASLASLASLANNTHIFHIFHIFELIELIELIELIELIELIELIELI
(Date:10/10/2008)..., NAIROBI, Kenya, Oct. 10 /PRNewswire-USNewswire/...lts of a global meeting convened to make,decisions...nd environment.,On 6-10 October 2008, the 2nd UNEP...reed on the elements that would form part of a glo...NEP Governing Council (GC) in February,2009, where...
(Date:10/10/2008)...Finding suggests need for more careful screening f...RIDAY, Oct. 10 (HealthDay News) -- Patients coping...risk for developing colorectal cancer sometime in ... syndrome is a conglomeration of three or four dis... for certain illnesses, including a number of canc...
(Date:10/10/2008)..., ANN ARBOR, Mich.---The University of Michigan ...f Health to develop the world,s leading resource o...ng compounds that will ultimately take computer-ai...will house the data needed to improve computer pro...ial new drugs, said Heather Carlson, associate pro...
(Date:10/10/2008)... PHILADELPHIA, Oct. 10 /PRNewswire/ -- The Mobi... ), a leading provider of on-site seated massage,s...al events, and special,affairs, announced today th...tern Pennsylvania and the greater Philadelphia met...e increasing interest in our on-site,seated, mass...
Breaking Medicine News(10 mins):Health News:Elements for a UN Global Framework on Mercury Agreed to 2Health News:Metabolic Syndrome Raises Colon Cancer Risk 75% 2Health News:Metabolic Syndrome Raises Colon Cancer Risk 75% 3Health News:U-M to house leading drug database 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2
(Date:10/10/2008)...Special Surgery researchers have found that statin... are suffering from pregnancy complications caused...a study in mice. In this autoimmune syndrome, the ..., the main components of cell membranes. This news... of the Journal of Clinical Investigation that i...
(Date:10/10/2008)...nformation technology have shaped not only how we ...w medicines. A project just funded by the National... drug design to the next level. , The University...hance the molecular data needed to develop compute...drug candidates. The data will be housed in a Web-...
(Date:10/10/2008)...ka MD, PhD, of Kyoto University and the Gladstone ...en another step forward in improving the possibili...ipotent stem (iPS) cell technology. , Previously...eprogrammed to become embryonic stem celllike usin...es required to reprogram the cells, and a virus to...
(Date:10/10/2008)... MILWAUKEE, MADISON Governor Jim Doyle today anno...sin research institutions to advance personalized ...y addresses diseases. The Wisconsin Genomics Initi... Marshfield Clinic, Medical College of Wisconsin (...nd Public Health (UWSMPH) and UW-Milwaukee (UWM). ...
Breaking Biology News(10 mins):Statins may prevent miscarriages 2Statins may prevent miscarriages 3New data resource to advance computer-aided drug design 2Yamanaka eliminates viral vector in stem cell reprogramming 2Governor Doyle announces historic genomic research collaboration 2Medical Breakthrough Doctor Discovers Penetrating Carrier That Eradicates Fungus 1723 1Medical Breakthrough Doctor Discovers Penetrating Carrier That Eradicates Fungus 1723 2ARYx Therapeutics Inc Announces Pricing of its Initial Public Offering 1718 1ARYx Therapeutics Inc Announces Pricing of its Initial Public Offering 1718 2Nabi Biopharmaceuticals Announces Successful Completion of NicVAX 28R 29 Phase 2b Trial 3B Drug Shows Statistically Significant Rates of Smoking Cessa 789 1Nabi Biopharmaceuticals Announces Successful Completion of NicVAX 28R 29 Phase 2b Trial 3B Drug Shows Statistically Significant Rates of Smoking Cessa 789 2Nabi Biopharmaceuticals Announces Successful Completion of NicVAX 28R 29 Phase 2b Trial 3B Drug Shows Statistically Significant Rates of Smoking Cessa 789 3Nabi Biopharmaceuticals Announces Successful Completion of NicVAX 28R 29 Phase 2b Trial 3B Drug Shows Statistically Significant Rates of Smoking Cessa 789 4Nabi Biopharmaceuticals Announces Successful Completion of NicVAX 28R 29 Phase 2b Trial 3B Drug Shows Statistically Significant Rates of Smoking Cessa 789 5Nabi Biopharmaceuticals Announces Successful Completion of NicVAX 28R 29 Phase 2b Trial 3B Drug Shows Statistically Significant Rates of Smoking Cessa 789 6Nabi Biopharmaceuticals Announces Successful Completion of NicVAX 28R 29 Phase 2b Trial 3B Drug Shows Statistically Significant Rates of Smoking Cessa 789 7FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change 1141 1FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change 1141 2FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change 1141 3FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change 1141 4FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change 1141 5
Other Contentsexonexonexonexonexperimentalexperimentalexperimentalexperimentalexperimentalexperimentalexperimentalexperimentalexperimentalexpressedexpressedexpressedexpressedexpressedexpressedexpressedexpressedextinctionextinctionextinctionextinctionextinctionfadfadeyeeyeeyeeyeeyeeyeeyeeyeeyefacilitatedfacilitatedfacilitatedfacilitatedfacilitated